Kera Sol Tears
Dry Eye Syndrome
Phase 2Active
Key Facts
About Surface Ophthalmics
Surface Ophthalmics is a private, pre-revenue biotech targeting the large and underserved dry eye disease market. The company has advanced three proprietary drug candidates through Phase II clinical trials involving over 550 patients, positioning itself to address a spectrum of DES presentations from episodic to chronic. Led by a team with deep ophthalmology experience, including founder Dr. Richard Lindstrom, Surface aims to provide eyecare professionals with a multi-faceted suite of treatments targeting signs, symptoms, and underlying causes of DES.
View full company profileTherapeutic Areas
Other Dry Eye Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| Tβ4 | ReGenTree | Not Specified (Pre-clinical/Clinical) |
| TREHAPAN® / Ocular Lubricants | Visufarma | Commercial |
| Voclosporin | Aurinia Pharmaceuticals | Phase 2 |